S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months

Athersys (ATHX) Stock Price, News & Analysis

$0.02
0.00 (0.00%)
(As of 12/8/2023 ET)
Compare
Today's Range
$0.02
$0.03
50-Day Range
$0.02
$0.44
52-Week Range
$0.02
$1.99
Volume
256,178 shs
Average Volume
1.70 million shs
Market Capitalization
$1.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

ATHX stock logo

About Athersys Stock (NASDAQ:ATHX)

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

ATHX Stock Price History

ATHX Stock News Headlines

Athersys (NASDAQ:ATHX) Now Covered by Analysts at StockNews.com
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Athersys shares delisted by Nasdaq Stock Market
Athersys crashes after bankruptcy warning
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Athersys Director Jane Wasman Appointed Board Chair
Is Athersys Inc (ATHX) Significantly Overvalued?
Why Is Athersys (ATHX) Stock Down 36% Today?
Athersys (NASDAQ: ATHX)
Athersys Restructures Debt with Supplier
See More Headlines
Receive ATHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/16/2023
Today
12/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATHX
Employees
24
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$5.50
Low Stock Price Target
$5.50
Potential Upside/Downside
+22,721.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-72,530,000.00
Pretax Margin
-46,304.93%

Debt

Sales & Book Value

Annual Sales
$5.32 million
Book Value
($1.33) per share

Miscellaneous

Free Float
61,700,000
Market Cap
$1.49 million
Optionable
Optionable
Beta
-0.78

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Daniel A. Camardo M.B.A. (Age 54)
    CEO, Secretary & Director
    Comp: $796.81k
  • Ms. Z. Kasey Rosado (Age 49)
    Interim Chief Financial Officer
    Comp: $1.51M
  • Ms. Maia A. Hansen M.B.A. (Age 54)
    M.S., Chief Operating Officer
    Comp: $962.57k
  • Senthil Ranganathan Ph.D.
    Vice President of Technical Operations
  • Mr. David Russ M.B.A.
    Vice President of Supply Chain, Finance & Administration
  • Dr. Manal Morsy M.B.A.
    M.D., PH.D., Executive VP & Head of Global Regulatory Affairs
  • Dr. Robert Mays Ph.D.
    Executive VP, Head of Regenerative Medicine & Neuroscience Programs
  • Mr. Rakesh Ramachandran MS
    Head of Information Technology & Communications and VP
  • Dr. Sarah Busch Ph.D.
    VP of Regenerative Medicine & Head of Business Development
  • Ms. Ellen Gurley
    Manager of Corporate Communications and Investor Relations














ATHX Stock Analysis - Frequently Asked Questions

Should I buy or sell Athersys stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATHX shares.
View ATHX analyst ratings
or view top-rated stocks.

What is Athersys' stock price target for 2024?

1 brokers have issued 1-year price targets for Athersys' stock. Their ATHX share price targets range from $5.50 to $5.50. On average, they expect the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 22,721.6% from the stock's current price.
View analysts price targets for ATHX
or view top-rated stocks among Wall Street analysts.

How have ATHX shares performed in 2023?

Athersys' stock was trading at $0.84 at the beginning of the year. Since then, ATHX stock has decreased by 97.1% and is now trading at $0.0241.
View the best growth stocks for 2023 here
.

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) released its earnings results on Thursday, November, 16th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter.

When did Athersys' stock split?

Athersys's stock reverse split before market open on Monday, August 29th 2022. The 1-25 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What is William (B.J.) Lehmann's approval rating as Athersys' CEO?

1 employees have rated Athersys Chief Executive Officer William (B.J.) Lehmann on Glassdoor.com. William (B.J.) Lehmann has an approval rating of 100% among the company's employees. This puts William (B.J.) Lehmann in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 65.0% of employees surveyed would recommend working at Athersys to a friend.

What other stocks do shareholders of Athersys own?
Who are Athersys' major shareholders?

Athersys' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (1.70%), Walleye Capital LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel A Camardo, Ismail Kola, Ivor Macleod, John J Harrington, John J Harrington, Laura K Campbell and William Lehmann Jr.
View institutional ownership trends
.

How do I buy shares of Athersys?

Shares of ATHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ATHX) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -